Purpose Recent evidence suggests that reaching the lowest achievable levels of
testosterone with androgen deprivation therapy delays disease progression and increases
overall survival in men with advanced prostate cancer. The aim of this analysis was to
compare posttreatment serum testosterone levels between patients undergoing subcapsular
orchiectomy and patients treated with the luteinizing hormone-releasing hormone agonist
triptorelin. Materials and Methods In this randomized clinical trial we included 58 …

The isolation and synthesis of the natural mammalian decapeptide luteinizing hormone-
releasing hormone (LHRH)[1] was quickly followed by the synthesis of analogs, mainly by
substitution of the sixth and tenth amino acids [2]. These analogs or agonists, sometimes
surnamed superagonists, release more LH for longer periods of time due to the increased
binding affinity to the LH receptors in the pituitary. The prolonged receptor occupancy by
these agonists leads to desensitisation of the pituitary LH cell receptors with subsequent …